TULSA, Okla., June 12, 2018 /PRNewswire-PRWeb/ -- Edison Healthcare has chosen Regenexx as their exclusive option for
Through their robust network of Smart Care Centers - Edison Healthcare is on a mission to help patients and employers avoid inefficient and unnecessary treatments. Adding Regenexx to their community of Smart Care Centers was both beneficial for the clients of Edison Healthcare and the patients they serve.
Each Smart Care Center consistently offers intelligent, thorough, and compassionate care for complex medical issues. By contracting directly with Smart Care providers around the world, Edison Healthcare is pioneering a new level of health care for patients and they are closing in on offering the most affordable medical services for employer groups.
With this new partnership, Regenexx is now the solution for Edison Healthcare patients who have been told they are in need of orthopedic surgery. Founding the field of Interventional Orthopedics, Regenexx offers a solution that provides a low-cost alternative to as many as 70% of orthopedic surgeries allowing employers to save more than 80% on orthopedic costs.
Tom Emerick, CEO and Co-Founder of Edison Healthcare, shared "Edison Healthcare welcomes Regenexx to the team. They offer a low cost and safe way to treat certain orthopedic problems. We expect employers and their employees to see great value in this program."
When asked about this innovative collaboration Regenexx Chief Executive Officer, Jason Hellickson said, "As a provider of the most advanced non-surgical orthopedic care available in the United States, Regenexx is excited to continue our mission of producing the best-possible patient outcomes for Edison Healthcare through successful alternatives to orthopedic surgery."
Contact us today to learn more. Edison Healthcare: 866-982-7988
SOURCE Edison Healthcare
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All